🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

RecruitingPhase 4Ages 50 Years - 90 YearsFemaleNational Taiwan University Hospital
NCT06938152 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 1\. Postmenopausal women aged 50-90 years * 2\. BMD T-score ≤ -3.0 at any lumbar vertebra * 3\. Physically and mentally capable of understanding and complying with the study protocol and follow-up * 4\. Signed informed consent Exclusion Criteria: * 1\. Previous osteoporosis treatment within the past two years, including Romosozumab, Teriparatide, Denosumab, Alendronate, Ibandronate, Zoledronic Acid, Risedronate, Raloxifene, or Bazedoxifene * 2\. Allergy to Romosozumab or Denosumab * 3\. Secondary osteoporosis * 4\. Autoimmune disease * 5\. Chronic steroid use (e.g., Chronic Obstruction Pulmonary Disease patients) * 6\. Hypercalcemia or hypocalcemia * 7\. Metabolic bone diseases * 8\. Primary or metastatic bone tumors * 9\. Cancer patients (except for in situ carcinoma and non-melanoma skin cancer, unless fully treated and in remission for five years) * 10\. Planned dental procedures (e.g., extractions, implants) within the next year * 11\. History of stent placement, myocardial infarction, stroke, or coronary artery disease * 12\. Renal disease (Creatinine \> 1.5 mg/dL) or dialysis patients * 13\. Smoking more than one pack per day (except for those who have quit for over ten years)
💊

What it tests

  • Romosozumab followed by Denosumab
  • Romosozumab and Denosumab Cycle Therapy
📍

Where

1 site
National Taiwan University Hospital
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy